Tivumecirnon

{
  "id": "MLC-T-ONC-017188",
  "term": "Tivumecirnon",
  "field": "Oncology and biomedicine",
  "definition": "An orally available, small molecule antagonist of C-C chemokine receptor type 4 (CCR4) with potential immunomodulatory and antineoplastic activities. Upon oral administration, tivumecirnon inhibits the binding of CCR4 to its signaling molecules, thereby blocking the recruitment of regulatory T cells (Tregs) to the tumor microenvironment (TME). This may abrogate the immunosuppressive effects of Tregs and promote an effective anti-tumor immune response. CCR4, a chemokine receptor normally expressed on circulating and tissue-resident T cells, is highly expressed on circulating Tregs and is associated with poor prognosis in certain cancers.",
  "synonyms": [
    "CCR4 inhibitor FLX475"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tivumecirnon/"
}